STAT3 and leukemia: Arsenic trioxide, which has been reported as a potential therapeutic agent for RA, was predicted to target MAPK1; it has also been approved to treat leukemia and reported to regulate the Treg and Th17 cell balance by modulating STAT3 expression in treatment-naïve RA patients [45].